Ratio secures equity financing

Ratio, Inc. has secured equity financing from regional angel investors and angel networks. The groups participating in the round include Wisconsin Investment Partners, The Golden Angels Network, Stateline Angels, and Central Illinois Angels. The company is keeping the round of financing open for 120 days and actively pursuing further investment.

“Companies like Ratio use innovation to make real, positive differences in the lives of real people. What can be better than that? The Golden Angels are glad to be a small part of Ratio. We hope for their success!”

"WIP is very impressed with Ratio's inventions and their applications in new and better ways to deliver pharmaceuticals and vaccines for a wide group of patients," states Dick Leazer of Wisconsin Investment Partners.

"Companies like Ratio use innovation to make real, positive differences in the lives of real people. What can be better than that? The Golden Angels are glad to be a small part of Ratio. We hope for their success!" expresses Tim Keane of The Golden Angels Network.

The capital will enable Ratio to further develop additional products and to recruit business development personnel with the necessary expertise to secure a partner in the therapeutic pharmaceutical space. The company believes that the bolus injection device, a clear fit with influenza vaccine, will attract considerable attention from potential partners.

The recent addition of Robert Lippert, CEO of ZARS Pharma, to the Board of Directors is a reflection of the company's ability to attract experienced professionals to the Ratio team. Mr. Lippert was warmly received by investors and is optimistic about the technology's potential.

Comments Mr. Lippert, "Ratio possesses the fundamentals needed to be successful within the growing drug delivery marketplace - Novel, proprietary technology, product scalability, and a simple solution to a specific drug delivery problem."